Video library
Real-world discussions with ECPs and patients
The MIEBO Experience
Find out how MIEBO helped a real patient, Rahnee, manage her evaporative DED so she could continue her active lifestyle more comfortably.
The MIEBO Difference
Find out what makes MIEBO different and why Dr. Marc Bloomenstein, OD, FAAO, chooses it for his patients with evaporative DED.
Peer perspectives
Eye to Eye: The MIEBO MOA
See what leading eye care professionals have to say about evaporative DED and how MIEBO can help.
Eye to Eye: The MIEBO Experience
Watch and learn from leading eye care professionals as they discuss what makes MIEBO different for ECPs and patients.
Eye to Eye: Breaking Down the Vicious Cycle of DED
Demystify the cycle of DED signs and symptoms by learning from leading eye care professionals about what drives it and how understanding the cycle can inform approaches to treatment.
Talking to Patients About MIEBO With Dr. McGee
Listen to Selina McGee, OD, FAAO, share how she sets expectations when introducing patients to MIEBO.
Talking to Patients About MIEBO With Dr. Gupta
Listen to Preeya Gupta, MD, share how she educates her patients on proper administration of MIEBO.
MIEBO Eyes on Eyecare Webinar With Dr. Schaeffer and Dr. Brujic
Take a deep dive into the science of MIEBO with 2 eye care experts.
MIEBO Eyes on Eyecare Webinar With Dr. Koetting and Dr. Lighthizer
See an overview of clinical data and a discussion of how MIEBO targets tear evaporation.
MIEBO Eyes on Eyecare Webinar With Dr. Ibach and Dr. Bloomenstein
Watch a summary of important information and an overview of clinical data provided by 2 expert eye care professionals.
MIEBO Eyes on Eyecare Webinar With Dr. Coats and Dr. Lievens
See 2 leading eye care professionals provide an introduction to MIEBO, including an overview of clinical data and the mechanism of action.
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for MIEBO.
You are now leaving MIEBO-ECP.COM
You are now leaving the MIEBO ECP website and are going to a website that Bausch + Lomb does not operate and to which Bausch + Lomb’s Privacy Policy does not apply.
Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to visit and does not endorse or monitor any content on such website.
INDICATION AND IMPORTANT
SAFETY INFORMATION
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for MIEBO.